United Kingdom (UK)
Recombinant monoclonal antibody to BCMA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma CA8.
UniProt Accession Number of Target Protein: Q02224
Alternative Name(s) of Target: CD269; BCM; TNFRSF17; Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; S307118G03; 118G03
Immunogen: The original mouse parental antibody 118G03 was generated by immunizing SJL mice with recombinant human BCMA/TNFRSF17-Fc chimera (R&D 193-Fc) by using the RIMMS method (Rapid immunization multiple sites). A chimeric version of this antibody was generated and it is called CA8.
Specificity: This antibody binds human and cynomolgus monkey BCMA and does not bind TACI or BAFF-R proteins. BCMA acts as a receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. BCMA expression is highest on terminally differentiated B cells. BCMA is involved in mediating the survival of plasma cells for maintaining long-term humoral immunity. It also activates NF-kappa-B and JNK. The expression of BCMA has been linked to a number of cancers, autoimmune disorders, and infectious diseases.
Application Notes: The binding characterization of this antibody towards human and cynomolgus monkey recombinant BCMA was done using ELISA (US9273141). The binding of the antibody to membrane bound BCMA expressed on HEK293, H929, OPM-2, JJN-3 and U266 cells was done using flow cytometry (US9273141). This antibody neutralizes binding of both BCMA ligands BAFF and APRIL, and subsequently blocks the induction of NF-κB signaling cascades (PMID: 26370838). The EC50 values for chimeric CA8 were calculated to be 0.695 μg/mL and 0.773 μg/mL respectively (US9273141). This antibody neutralized both BAFF and APRIL induced NfkappaB cell signaling in H-929 cells. This antibody was also reported to kill BCMA expressing ARH77 cells via ADCC. This antibody was also used in the generation of an antibody-drug conjugate for possible application in the treatment of multiple myeloma (US9273141).
Antibody first published in:
Yu-Tzu Tai et al. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015 Nov; 7(11): 1187–1199. PMID:26370838
Note on publication:
Discusses the novel immunotherapy treatment for multiple myelomas by targeting a cell surface protein like B-cell maturation antigen.